J&J highlights Tremfya’s efficacy against psoriatic arthritis in Phase 3 trial win
Johnson & Johnson (NYSE:JNJ) on Friday announced a Phase 3 trial win for its anti-inflammatory therapy Tremfya, highlighting ...
MPR4d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
MyChesCo on MSN13d
FDA Approves TREMFYA® for Crohn’s Disease, Offering New Treatment Options
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
PMLive4d
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...
FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
The American Journal of Managed Care13d
FDA Approves Guselkumab for Adult Patients With Crohn Disease
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Managed Healthcare Executive13d
FDA Approves Tremyfa to Treat Active Crohn’s Disease
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Yahoo Finance7d
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...
TREMFYA® (Guselkumab) Receives Positive CHMP Opinion For Treatment Of Patients With Moderately To Severely Active Crohn’S Disease
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...
U.S. News & World Report10d
FDA Approves Tremfya for Active Crohn Disease in Adults
MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This ...
manilatimes7d
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn's Disease
Accessed March 2025. 3 J&J Data on file (RF-433976). European Medicines Agency. Updated TREMFYA Summary of Product Characteristics. Accessed March 2025. 5 EU SmPC: European Medicines Agency. TREMFYA ...